177 Lu-Labeled Bivalent Ligands of Prostate-Specific Membrane Antigen for Endoradiotherapy of Prostate Cancer
Molecular Pharmaceutics · 05.02.2024 · 21 (2) · 883-894
DOI: 10.1021/acs.molpharmaceut.3c00987 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 28.12.2023. Verfasst von Ruoxue Dai und 7 weiteren Autor:innen. Beteiligte Einrichtung: GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical U…. Hauptthemen laut MEDLINE: Prostate, Prostatic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China, National Isotope Engineering Research Center of China.
Abstract (Originalsprache)
Recently, we developed a bivalent prostate-specific membrane antigen (PSMA) radioligand ([18F]AlF-Bi-PSMA), which showed higher tumor uptake and retention in PSMA-positive mouse models than the clinically used radioligands, [68Ga]Ga-PSMA-11 and [18F]PSMA-1007. Here, we developed two 177Lu-labeled bivalent PSMA ligands with (DOTA-Alb-Bi-PSMA) or without an albumin-binding motif (DOTA-Bi-PSMA) to enhance radiotherapeutic efficacy with minimal toxicity. The results demonstrated that both 177Lu-labeled bivalent radioligands showed good stability, high binding affinity, and PSMA-targeting specificity in vitro. Compared with [177Lu]Lu-PSMA-617, both [177Lu]Lu-Bi-PSMA and [177Lu]Lu-Alb-Bi-PSMA showed a higher area under the curve (AUC) of tumor accumulation and superior therapeutic efficacy. However, [177Lu]Lu-Alb-Bi-PSMA exhibited a dose-dependent increase in acute damage to kidneys. In terms of the radionuclide therapy efficacy and side effects, [177Lu]Lu-Bi-PSMA exhibited well-balanced action with high tumor-to-organs AUC ratios, resulting in remarkable therapeutic efficacy and negligible side effects. These promising results warrant further investigations to achieve the clinical translation of [177Lu]Lu-Bi-PSMA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, P. R. China.
- School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, P. R. China.
ORCID-Profile: Hongsheng Li
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
- National Isotope Engineering Research Center of China
Zitieren
APA
Dai, R., Cai, Z., Hu, R., Huang, Y., Fu, L., Yang, J., Hu, K., & Li, H. (2024). 177 Lu-Labeled Bivalent Ligands of Prostate-Specific Membrane Antigen for Endoradiotherapy of Prostate Cancer. Molecular Pharmaceutics, 21(2), 883-894. https://doi.org/10.1021/acs.molpharmaceut.3c00987
Vancouver
Dai R, Cai Z, Hu R, Huang Y, Fu L, Yang J, et al. 177 Lu-Labeled Bivalent Ligands of Prostate-Specific Membrane Antigen for Endoradiotherapy of Prostate Cancer. Molecular Pharmaceutics. 2024;21(2):883-894. doi:10.1021/acs.molpharmaceut.3c00987
BibTeX
@article{Dai2024,
author = {Dai, Ruoxue and Cai, Zhikai and Hu, Rui and Huang, Yueqi and Fu, Lilan and Yang, Jiaqi and Hu, Kongzhen and Li, Hongsheng},
title = {177 Lu-Labeled Bivalent Ligands of Prostate-Specific Membrane Antigen for Endoradiotherapy of Prostate Cancer},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {2},
pages = {883--894},
doi = {10.1021/acs.molpharmaceut.3c00987}
}
EUVIMED